Financial Navitoclax disclosures: Funding for this study was provided by Bristol-Myers Squibb. Medical

writing assistance was provided by Isabelle Kaufmann of ArticulateScience and was funded by Bristol-Myers Squibb. Publication assistance was provided and funded by Bristol-Myers Squibb Australia. K TOKES,1 S QUADRI,1 P CAHILL,2 G CHIU,2 A IVANOV,1 H TANG1 1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2GC Global Research, Brooklyn, NY, USA Introduction: In the US, an estimated 2.2 million people have chronic hepatitis B (CHB) and about half are Asian Americans. Previous research has shown poor disease awareness and differing attitudes towards CHB treatment among Asian Americans. This study therefore looks at the perceptions of CHB treatment among this population, and the relative importance of different clinical and economic attributes of oral antivirals for CHB. Methods: Qualified participants from the Chinese, Korean and Vietnamese communities of New York metropolitan area, San Francisco/Bay area and the Los Angeles/Orange County area were selected to receive a face-to-face structured survey. The surveys were administered by trained interviewers from each learn more participating ethnicity and the data were captured in an online database. Statistical

analysis was performed using a Hierarchical Bayesian model to estimate the relative importance of different attributes. Results: 252 patients with CHB (36% Chinese, 33% 上海皓元医药股份有限公司 Vietnamese, 31% Korean) participated in the study; 56% were treatment naïve and 44% were being treated

with an oral antiviral for CHB. The majority of participants (88%) believed that if left untreated, CHB can lead to serious liver damage, although only 72% believed that there are effective medications to treat CHB. In addition, 39% showed reluctance to be on long-term therapy because of side-effect concerns. When asked about the different attributes that are important for them to consider before being treated for CHB, long-term risk of kidney damage was given the highest relative importance (38%), followed by cost of the medication (23.4%), long-term risk of bone thinning (18%), long-term efficacy (9%), time-on-market for US (6.8%) and level of use (4.9%). These results were consistent across the different ethnicities within the study. Conclusions: Patients need access to improved education regarding CHB disease progression, its management, disease outcomes and the importance of long-term treatment. Financial disclosures: Funding for this study was provided by Bristol-Myers Squibb. Medical writing assistance was provided by Esther Race of ArticulateScience and was funded by Bristol-Myers Squibb.